CompoAtlas

Tokkyo Anabolic Stack

On sale on the US market (according to the DSLD)

Tokkyo Nutrition, food supplement from the US market

Tokkyo Anabolic Stack (Tokkyo Nutrition), a food supplement au code-barres 896896002415, is described by its US market label. If sold in France, it would be subject to 5 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.

Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.

Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.

If this product were sold in France

A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.

Label composition

Brand
Tokkyo Nutrition
Barcode
896896002415
Form
Capsule
One serving
3 capsules
Servings
up to 2 servings per day
Other ingredients (in English, as written)
Gelatin, Magnesium Stearate
Ingredient (as written, in English)CategoryPer serving
Tokkyo Testosterone StackBlend2,250 mg
Tribulus (Tribulus terrestris)Plantnot stated
Fenugreek 4:1 extract (Trigonella foenum-graecum)Plantnot stated
Fadogia Agrestis ExtractPlantnot stated
IcarrinOther substancenot stated
Divanil(TM)Other substancenot stated
Peruvian Maca (Lepidium meyenii)Plantnot stated
Magnesium AspartateOther substancenot stated
Zinc AspartateOther substancenot stated
Vitamin B6Vitaminnot stated
Tokkyo Estrogen Blocking StackBlend110 mg
Trans-ResveratrolOther substancenot stated
5,7-DihydroxyflavoneOther substancenot stated
QuercetinOther substancenot stated
5-Androsten-3Beta-Ol-17-OneOther substancenot stated
Tokkyo DHT Blocking StackBlend270 mg
Pygeum Africanum Extract (Prunus africana)Plantnot stated
Saw Palmetto Berry Extract (Serenoa repens)Plantnot stated
White Button MushroomOthernot stated

Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.

This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Tribulus
    Read the warning, when it applies and the studies cited

    TRIBULUS - TRIBULUS TERRESTRIS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products except Vrsya (aphrodisiac for men).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Chen and Chen 2004).

    Sources cited by Health Canada (1)
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Condition of application: Traditional Chinese Medicine.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have qi or blood deficiency (Bensky et al. 2004).

    Sources cited by Health Canada (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Contraindications

    Condition of application: Traditional Chinese Medicine.

    Do not use if you have low blood pressure or liver deficiency (Bensky et al. 2004; Chen and Chen 2004).

    Sources cited by Health Canada (2)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.
    • Chen JK, Chen TT. Chinese Medical Herbology and Pharmacology. Crampton L, editor. City of Industry (CA): Art of Medicine Press Inc.; 2004.

    Known adverse reactions

    Condition of application: All products.

    Stop use if hypersensitivity/allergy occurs (Bensky et al. 2004)

    Sources cited by Health Canada (1)
    • Bensky D, Clavey S, Toger E, Gamble A, editors. Chinese Herbal Medicine Materia Medica. 3rd edition. Seattle (WA): Eastland Press Inc; 2004.

    Condition of application: All products except Mutrala (diuretic).

    When using this product diuretic effect may occur.

    Health Canada monograph dated 29 May 2026

  • Fenugreek 4:1 extract
    Read the warning, when it applies and the studies cited

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant (Gardner and McGuffin 2013; Brinker 2010; Mills et al. 2006; Hoffman 2003; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Gardner Z, McGuffin M, editors. American Herbal Products Association's Botanical Safety Handbook. 2nd edition. Boca Ration (FL): Taylor and Francis Group; 2013.
    • Mills E, Duguoa J, Perri D, Koren G. Herbal Medicines in Pregnancy and Lactation. An Evidence-Based Approach. New York (NY): Taylor and Francis; 2006.

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have diabetes (Brinker 2010; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.

    Health Canada monograph dated 29 May 2026

    FENUGREEK - TRIGONELLA FOENUM-GRAECUM - Topical

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 29 May 2026

  • Peruvian Maca
    Read the warning, when it applies and the studies cited

    Maca - Lepidium Meyenii

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Applies to products providing 0.6 g or more dried root/hypocotyl, per day.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have a blood pressure condition (Valentova et al. 2008).

    Sources cited by Health Canada (1)
    • Valentova K, Stejskal D, Bartek J, Dvoráckova S, Kren V, Ulrichova J, Simanek V. Maca (Lepidium meyenii) and yacon (Smallanthus sonchifolius) in combination with silymarin as food supplements: in vivo safety assessment. Food and Chemical Toxicology 2008;46(3):1006-1013. PubMed Randomised trial

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking blood thinners (Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Sources cited by Health Canada (2)
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Condition of application: Healthy mood balance; Sexual health.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have psychological disorders such as anxiety or depression (Brotto 2010; Gonzales and Gonzales-Castaneda 2009; Dording et al. 2008).

    Sources cited by Health Canada (3)
    • Brotto LA. The DSM diagnostic criteria for hypoactive sexual desire disorder in women. Archives of Sexual Behavior 2010;39(2):221-239. PubMed Review article
    • Dording CM, Fsher L, Papakostas G, Farabaugh A, Sonawalla S, Fava M, Mischoulon D. A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunction. CNS Neuroscience Therapy and Therapeutics 2008;14(3):182-191. PubMed Randomised trial
    • Gonzales GF, Gonzales-Castaneda GC. The Methyltetrahydro-{beta}-Carbolines in Maca (Lepidium meyenii). Evidence Based Complementary Alternative Medicine 2009;6(3):315-316. PubMed

    Health Canada monograph dated 27 September 2024

  • Pygeum Africanum Extract
    Read the warning, when it applies and the studies cited

    PYGEUM - PRUNUS AFRICANA

    Route of administration: Oral

    Cautions and warnings

    Condition of application: Standardized extracts making a claim for symptoms of benign prostatic hyperplasia (adult males).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (Goldman and Ausiello 2004).

    Sources cited by Health Canada (1)
    • Goldman L, Ausiello D. Cecil Textbook of Medicine. 22nd edition. Philadelphia (PA): Saunders; 2004.

    Condition of application: Non-standardized preparations for adults (i.e., including women) (safety only).

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Health Canada monograph dated 26 June 2026

  • Saw Palmetto Berry Extract
    Read the warning, when it applies and the studies cited

    SAW PALMETTO – SERENOA REPENS

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All subpopulations.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Adult males only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use to exclude a diagnosis of prostate cancer (USP-NF 2024; Mills and Bone 2005).

    Sources cited by Health Canada (2)
    • Mills S, Bone K. The Essential Guide to Herbal Safety. St. Louis (MO): Elsevier Churchill Livingstone; 2005.
    • USP-NF 2024: United States Pharmacopeia and the National Formulary. Rockville (MD): The United States Pharmacopeial Convention, Inc.; 2024.

    Condition of application: Adult females only.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are taking oral contraceptives or hormone replacement therapy (UpToDate 2024).

    Sources cited by Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Contraindications

    Condition of application: Adult females only.

    Do not use if you are pregnant, breastfeeding, or attempting to conceive (UpToDate 2024).

    Sources cited by Health Canada (1)
    • UpToDate 2024. UpToDate database. Clinical use of Saw palmetto. [Consulted 2024 December 5]. Available from : https://www.uptodate.com/contents/clinical-use-of-saw-palmetto?search=saw%20palmetto&source=search_result&selectedTitle=1%7E9&usage_type=default&display_rank=1

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).

Photograph the packaging

Brand : Tokkyo Nutrition

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Tokkyo Anabolic Stack (Tokkyo Nutrition): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/896896002415-tokkyo-anabolic-stack-tokkyo-nutrition, updated 23 May 2014.

List recorded in 2014. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line